More than half of the direct expenditure on diabetes is associated with complications (Guest blog)

In the 2019-2022 period the average annual expenditure on diabetes amounted to 174 million euros. The average annual growth rate of direct spending on diabetes and its complications was 12.5 percent over the period studied.

"For me as a diabetologist, the key message is that significant resources are spent on treating the chronic complications of diabetes, so it would make sense to redirect as much of this money as possible to preventing these complications so that money can be spent on people who are still healthy and maintaining their health," commented Prof. Dr. Tadej Battelino.

Read more here.

The Rare Disease (RD) Moonshot was set up to boost public private collaborations in the areas where there are no treatment options and there is no R&D going on.

The RD Moonshot partners put together three sets of recommendations to highlight where public-private collaborations can add most value.

Click here to learn more on the recommendations for accelerating translational research for rare diseases.